Tucson, AZ, July 29, 2021 --(PR.com)-- NuvOx Pharma, a Tucson-based biopharmaceutical company, has received notice from the FDA that they may proceed with a Phase II clinical trial of their drug, NanO2TM, in ischemic stroke.
top of page
Search
Recent Posts
See AllTucson, AZ, September 18th, 2023 NuvOx Therapeutics (“NuvOx”) announced that it has closed an oversubscribed convertible notes round, raising approximately $7M out of the originally planned $5M. In th
Tucson, AZ, August 28th, 2023 NuvOx Pharma announced publication of a research article, “Dodecafluoropentane Emulsion as a Radiosensitizer in Glioblastoma Multiforme” in Cancer Research Communications
Tucson, AZ, August 4th, 2023 - NuvOx Pharma (NuvOx), a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, annou
bottom of page